Marvel Biosciences Corp (MRVL) AI Stock Analysis

• Market Cap: C$6.27M
• Dividend Yield: N/A
• Average Volume (3M): 35.62K
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 44,803,730
• 10 Day Avg. Volume: 30,690
• 30 Day Avg. Volume: 35,622
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Marvel Biosciences Corp's stock is significantly hampered by severe financial distress, as evidenced by negative income and high leverage. The technical analysis confirms a bearish trend, while the valuation highlights ongoing unprofitability. Immediate strategic initiatives are crucial for financial stabilization.

Marvel Biosciences Corp Business Overview & Revenue Model

Company Description

Alphanco Venture Corp is a capital pool company based in Canada. It proposes to identify and evaluate corporations, businesses or assets for acquisition and once identified and evaluated to negotiate an acquisition or participation subject to receipt of regulatory and shareholder approval, as applicable.

How the Company Makes Money

Marvel Biosciences Corp makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue by licensing its technologies and products to pharmaceutical companies and through partnerships that may include milestone payments, royalties, and collaboration fees. Additionally, Marvel Biosciences may engage in research and development services for other organizations, contributing to its revenue streams. The company's success is heavily contingent on its ability to advance its drug pipeline through clinical trials and obtain regulatory approvals, which can lead to lucrative licensing deals and market entry of its therapeutics.

Marvel Biosciences Corp Financial Statement Overview

Summary

Marvel Biosciences Corp is facing significant financial challenges, with consistent negative income, high debt-to-equity ratio, and reliance on external funding. These factors indicate financial distress and potential solvency issues.

Income Statement

Marvel Biosciences Corp has consistent negative income figures with no revenue, indicating a lack of operational profitability. The company is incurring significant losses, with a negative net income and gross profit margin. These metrics highlight ongoing financial challenges in generating revenue and controlling costs.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial distress and potential solvency issues. The company has a high debt-to-equity ratio due to significant liabilities compared to equity, increasing financial risk. These factors suggest a need for improved capital management and reduction of liabilities.

Cash Flow

Cash flow from operations is negative, reflecting challenges in generating cash from core activities. The free cash flow is also negative, but financing cash flow is positive, indicating reliance on external funding. This reliance poses risks if external financing becomes constrained.

Breakdown
TTM	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-84.98K	-887.52K	-1.38M	-613.10K	-265.20K	0.00
	EBIT
-489.74K	-2.32M	-2.54M	806.33K	-954.20K	-100.05K
	EBITDA
-725.07K	-2.25M	-2.51M	-1.25M	-1.02M	-100.05K
	Net Income Common Stockholders
-1.41M	-2.29M	-2.55M	-3.04M	-955.66K	-98.04K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
83.29K	556.62K	593.21K	2.39M	224.81K	415.23K
	Total Assets
228.65K	672.39K	913.54K	2.47M	295.99K	417.24K
	Total Debt
1.71M	1.00M	0.00	0.00	0.00	0.00
	Net Debt
1.63M	443.38K	-593.21K	-2.39M	-224.81K	-6.23K
	Total Liabilities
3.31M	2.39M	718.00K	112.48K	177.18K	3.08K
	Stockholders Equity
-3.08M	-1.72M	195.54K	2.36M	118.80K	414.16K
Cash Flow		Free Cash Flow
-1.20M	-1.33M	-2.19M	-1.37M	-538.53K	-41.80K
	Operating Cash Flow
-1.20M	-1.33M	-2.19M	-1.37M	-538.53K	-41.80K
	Investing Cash Flow
0.00	0.00	0.00	381.57K	0.00	-409.00K
	Financing Cash Flow
968.64K	1.30M	394.00K	3.16M	763.17K	457.03K

Marvel Biosciences Corp Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MRVL, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.15, and above the 200-day MA of 0.13, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.17 is Neutral, neither overbought nor oversold. The STOCH value of 71.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MRVL.

Marvel Biosciences Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.93B	0.23	-53.86%	2.46%	21.78%	-1.36%
ALY	44 Neutral	C$4.86M	―	-62.10%	―	-60.08%	43.19%
PHA	44 Neutral	C$3.33M	―	-160.58%	―	44.96%	-827.30%
MRVL	32 Underperform	C$6.27M	―	45.74%	―	―	―

Marvel Biosciences Corp Corporate Events

Marvel Biosciences Secures Patent Allowance for MB-204 in China

Marvel Biosciences Corp. announced that the Chinese patent office has issued a notice of allowance for its lead compound MB-204, a novel fluorinated derivative of the Parkinson’s drug Istradefylline, marking the first worldwide allowance for this family of patents. This development underscores Marvel’s progress in securing intellectual property protection as it prepares to advance MB-204 into clinical trials, potentially strengthening its position in the pharmaceutical industry and benefiting stakeholders interested in neurological disease treatments.

Marvel Biosciences Announces $2.5 Million Private Placement

Marvel Biosciences Corp. announced its intention to complete a non-brokered private placement of common shares, aiming to raise between $1,935,000 and $2,500,000. The proceeds are expected to fund phase 1 clinical trials of their lead compound MB-204, as well as cover general administrative expenses and working capital. The offering is subject to regulatory approvals and will be conducted under specific exemptions in Canada, excluding Quebec. The engagement of Abingdon Capital as a finder, with potential compensation and advisory roles, further indicates strategic partnerships for Marvel’s financing endeavors.